Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and other accrued liabilities $2,049,936 $2,150,980 Accrued clinical expense 1,321,786 1,865,773 Accrued compensation 415,007 537,215 Accrued restructuring charges 59,993 191,170 Current portion of deferred rent 23,308 1,409,513 Current portion of deferred revenue 2,083 27,083 ----- ------ Total current liabilities 3,872,113 6,181,734 Non-current portion of deferred rent 87,755 110,919 Commitments Stockholders' equity: Convertible preferred stock 56,163,436 - Common stock 3,442 3,441 Additional paid-in capital 297,092,539 322,671,604 Accumulated other comprehensive income 127 7,841 Accumulated deficit (347,433,609) (316,191,710) ------------ ------------ Total stockholders' equity 5,825,935 6,491,176 --------- --------- Total liabilities and stockholders' equity $9,785,803 $12,783,829 ========== =========== Note 1: The condensed consolidated balance sheet as of December 31, 2008 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2008.

                               SUNESIS PHARMACEUTICALS, INC.
                   CONDENSED CO
'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... three large odour control systems for waste water treatment plants ... are consistent with the market resurgence in North ... CEO. "After a difficult period of restraint in our core ... sales growth. Our lower cost structure, technology improvements and supply ...
(Date:9/2/2014)... Sept. 2, 2014  Spherix Incorporated (SPEX) -- an intellectual property ... intellectual property, today announced that the United States Patent ... Company in the month of August that are part ... The issued patents are: , ... August 19, 2014; and , U.S.RE45,095 issued August ...
(Date:9/2/2014)... 02, 2014 The inventors of tinAway, ... chronic tinnitus are seeking support for development costs through ... platform ( http://igg.me/at/tinaway ), was launched on September 1, ... ‘mHealth’ app and is based on ten years of ... of biomedical and software engineers, Dr. Ian Dixon and ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 The ... $1,712.1 million by 2019 from $1,070.7 million in ... 2014 to 2019. The global oligonucleotide synthesis market ... services, applications, end users, and geography. The synthesized ... growth rate in the oligonucleotide synthesis market during ...
Breaking Biology Technology:United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 59.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... ET, MOUNTAINSIDE, N.J., Feb. 26 National ... that its President,Michael Cohen will present a Keynote ... Institutions and Development Stage,Biotech Companies," at the Inaugural ... Collaborations & Careers in Stem Cell Science,February 28- ...
... 26 Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... the science of healthy aging, today announced,that results of ... February issue of the Journal of Drugs in Dermatology., ... and tolerance of,topical Pyratine-6(TM) over 12 weeks for improving ...
... BioVascular, Inc., a company focused,on developing novel ... Christopher M. Bussineau, Ph.D., to the,position of vice ... position of vice president, business development and nonvascular,operations., ... skill and experience to,BioVascular that will allow us ...
Cached Biology Technology:National Stem Cell Holding, Inc. to Present Keynote Address at The Stem Cell Partnering Series Inaugural Meeting in San Diego 2National Stem Cell Holding, Inc. to Present Keynote Address at The Stem Cell Partnering Series Inaugural Meeting in San Diego 3Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology 2Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology 3BioVascular, Inc. Expands Executive Team 2
(Date:9/2/2014)... their propensity for eating anything, including each other, camel ... from North Carolina State University finds that non-native camel ... United States. , "The good news is that camel ... to humans," says Dr. Mary Jane Epps, a postdoctoral ... paper about the research. , The research stems from ...
(Date:9/1/2014)... us fat? An increasing amount of research shows an ... a more sedentary lifestyle. Now, a new Cornell University ... Some TV programs might lead people to eat twice ... you,re watching an action movie while snacking your mouth ... lead author on the new article just published in ...
(Date:9/1/2014)... after birth, every child in the U.S. undergoes a ... conditions, including sickle cell disease. Thousands of children born ... many suffer and die from the disease each year. ... to at least some of those deaths. , ... in the lab of George Whitesides, the Woodford L. ...
Breaking Biology News(10 mins):Researchers find Asian camel crickets now common in US homes 2Can action movies make you fat? 2Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3
... nearly complete collection of genes for a species of reef-building ... from The University of Texas at Austin. The scientists ... corals from around the world and how they respond, at ... of the most important questions for coral biologists is whether ...
... A genetic variant that substantially improves survival of ... Lou Gehrig,s disease, has been indentified by a consortium ... of Neurology and Robert Brown, MD, DPhil, Chair and ... School. Discovery of the KIFAP3 gene variant is reported ...
... ambitious effort in avian conservation is underway this spring ... watershed. A legion of highly skilled volunteer ornithologists ... best stopover sites for migrating birds in the southern ... on Neotropical migrants. These songbirds summer in the subarctic ...
Cached Biology News:Most extensive genetic resource for reef-building coral created 2UMMS researchers isolate first 'neuroprotective' gene in patients with amyotrophic lateral sclerosis 2Conservationists seek to identify prime stopover sites for migrating birds 2Conservationists seek to identify prime stopover sites for migrating birds 3
... Includes: Sufficient library for 10 separate ... independent sequences, -28 gIII Sequencing Primer ... -96 gIII Sequencing Primer (100 pmol), ... coli strain ER2738, Control target (Streptavidin) ...
... 15-20 enhancements when used as directed, ... is designed to amplify the desired signal detected by ... proteins with low expression., Membrane Enhancement ... the membrane; 1x solution; 250 ml, ...
... Blot Recycling Kit is effective for ... that have been developed with chemiluminescence ... It is not recommended for stripping ... as it is not possible to ...
... to siRNA library screening, optimal ... identified and verified for each ... CellReady siRNA Transfection Optimization Kit, ... optimizing transfection conditions in 96 ...
Biology Products: